Arexvy is a vaccine used to prevent certain lower respiratory infections caused by respiratory syncytial virus (RSV). Arexvy’s cost may depend on factors such as whether you have health insurance and ...

Arexvy (respiratory syncytial virus vaccine, adjuvanted) is a brand-name intramuscular injection that’s prescribed to help prevent a lung infection that’s caused by RSV infection in adults. The cost ...

Arexvy, a respiratory syncytial virus (RSV) vaccine, is a brand-name intramuscular injection. It’s prescribed to help prevent lower respiratory infections from RSV. Arexvy has no known interactions ...

What Is Arexvy, and Why Does It Matter? Arexvy is a vaccine that helps protect against serious lung illness caused by respiratory syncytial virus (RSV). The FDA has expanded its use to include people ...

Data from the Phase III AReSVi-006 clinical trial found that Arexvy offered a cumulative efficacy of 62.9% against lower respiratory tract disease caused by respiratory syncytial virus. Results from ...

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection1* PHILADELPHIA, March 13, 2026--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that ...

The FDA assigned a Prescription Drug User Fee Act action date of June 7, 2024, to an application that would expand the indication of Arexvy to include adults 50-59 years with an increased risk of ...

According to GSK, an FDA approval decision is expected in the first half of 2026. The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) ...

Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's ...

The US has approved the first vaccine for respiratory syncytial virus (RSV) for people aged 60 and over. On Wednesday the Food and Drug Administration (FDA) approved the use of Arexvy in the country.

In the US, an estimated 21 million adults under 50 have at least one risk factor for severe RSV infection1* The annual RSV burden among US adults aged 18–49 years is about 17,000 hospitalizations, 277 ...